PL374439A1 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number: PL374439A1
Authority: PL; Poland
Prior art keywords: antibodies
Prior art date: 2002-07-01

Application number

PL03374439A

Other languages

Polish (pl)

Inventor

Avigdor Levanon

Rachel Ben-Levy

Daniel Plaksin

Esther Szanton

Yocheved Hagai

Mar-Chaim Hagit Hoch

Original Assignee

Savient Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-01

Filing date

2003-06-30

Publication date

2005-10-17

2003-06-30 Application filed by Savient Pharmaceuticals, Inc. filed Critical Savient Pharmaceuticals, Inc.

2005-10-17 Publication of PL374439A1 publication Critical patent/PL374439A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)

PL03374439A 2002-07-01 2003-06-30 Antibodies and uses thereof PL374439A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18903202A	2002-07-01	2002-07-01

Publications (1)

Publication Number	Publication Date
PL374439A1 true PL374439A1 (en)	2005-10-17

Family

ID=29999594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03374439A PL374439A1 (en)	2002-07-01	2003-06-30	Antibodies and uses thereof

Country Status (12)

Country	Link
EP (1)	EP1534332A4 (en)
JP (1)	JP2005536199A (en)
KR (1)	KR20060011925A (en)
CN (1)	CN1678347A (en)
AU (1)	AU2003263764A1 (en)
BR (1)	BR0312483A (en)
CA (1)	CA2491363A1 (en)
IL (1)	IL166063A0 (en)
MX (1)	MXPA05000272A (en)
PL (1)	PL374439A1 (en)
RU (1)	RU2005101621A (en)
WO (1)	WO2004003166A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20031714A1 (en) *	2003-09-05	2005-03-06	Gentium Spa	FORMATIONS FOR ANTITUMORAL ACTION.
AR048840A1 (en) *	2004-05-11	2006-05-31	Boehringer Ingelheim Int	INDUCTIVE EPITHOPES OF DEATH OF CELLS T
US20070298034A9 (en) *	2005-12-09	2007-12-27	Angela Widom	Sulfotyrosine specific antibodies and uses therefor
JP6069209B2 (en)	2010-11-12	2017-02-01	ジェンティウムソシエタアレスポンサビリタリミタータ	Defibrotide for use in the prevention and / or treatment of graft versus host disease (GVHD)
BR112013031892A2 (en)	2011-06-13	2016-11-22	Abgenomics Cooperatief Ua	anti-psgl-1 antibodies and their use
DK2864496T4 (en)	2012-06-22	2021-01-04	Gentium S R L	EUGLOBULIN-BASED PROCEDURE FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTID
EP3026122A1 (en)	2014-11-27	2016-06-01	Gentium S.p.A.	Cellular-based method for determining the potency of defibrotide
KR101896751B1 (en) *	2015-12-01	2018-10-04	주식회사 엘지화학	Thermoplastic resin, method for preparing the resin and thermoplastic resin composition comprising the resin
BR112021000934A2 (en) *	2018-07-20	2021-04-27	Pierre Fabre Medicament	receiver for sight
CN111715409B (en) *	2020-07-01	2021-07-23	中南大学	A combined lead inhibitor of fine-grained galena and its application
CN116333100A (en) *	2022-10-31	2023-06-27	南京欧凯生物科技有限公司	A rapid purification method of recombinant human IgM antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002528513A (en) *	1998-10-30	2002-09-03	ジェネティックス・インスチチュート・インコーポレーテッド	Inhibition of cytotoxic T-cell differentiation by P-selectin ligand (PSGL) antagonists
MXPA02009271A (en) *	2000-03-24	2003-03-12	Genetics Inst	A novel p selectin glycoprotein ligand (psgl 1) binding protein and uses therefor.

2003
- 2003-06-30 JP JP2004518132A patent/JP2005536199A/en active Pending
- 2003-06-30 KR KR1020047021603A patent/KR20060011925A/en not_active Withdrawn
- 2003-06-30 CA CA002491363A patent/CA2491363A1/en not_active Abandoned
- 2003-06-30 RU RU2005101621/13A patent/RU2005101621A/en not_active Application Discontinuation
- 2003-06-30 PL PL03374439A patent/PL374439A1/en not_active Application Discontinuation
- 2003-06-30 EP EP03762258A patent/EP1534332A4/en not_active Withdrawn
- 2003-06-30 CN CNA038204029A patent/CN1678347A/en active Pending
- 2003-06-30 MX MXPA05000272A patent/MXPA05000272A/en unknown
- 2003-06-30 BR BR0312483-5A patent/BR0312483A/en not_active IP Right Cessation
- 2003-06-30 WO PCT/US2003/020602 patent/WO2004003166A2/en not_active Ceased
- 2003-06-30 AU AU2003263764A patent/AU2003263764A1/en not_active Abandoned
2004
- 2004-12-30 IL IL16606304A patent/IL166063A0/en unknown

Also Published As

Publication number	Publication date
CN1678347A (en)	2005-10-05
JP2005536199A (en)	2005-12-02
EP1534332A4 (en)	2006-11-22
KR20060011925A (en)	2006-02-06
WO2004003166A2 (en)	2004-01-08
IL166063A0 (en)	2006-01-15
BR0312483A (en)	2005-08-09
WO2004003166A3 (en)	2005-03-10
RU2005101621A (en)	2005-11-20
AU2003263764A1 (en)	2004-01-19
CA2491363A1 (en)	2004-01-08
EP1534332A2 (en)	2005-06-01
MXPA05000272A (en)	2005-09-20

Publication	Publication Date	Title
IL225633A0 (en)	2014-03-31	Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en)	2007-03-07	Anti-addl antibodies and uses thereof
HUS1800030I1 (en)	2018-07-30	Immunoglobulin variants and uses thereof
EP1551877A4 (en)	2006-01-18	Taci antibodies and uses thereof
AU2003299778A8 (en)	2004-07-22	Antibodies against gpr64 and uses thereof
EP1539941A4 (en)	2006-11-29	Adzymes and uses thereof
EP1494693A4 (en)	2006-08-02	Cripto-specific antibodies
LT2368907T (en)	2016-10-25	Anti-Abeta antibodies and their use
PL375405A1 (en)	2005-11-28	Antibodies
IL172871A0 (en)	2006-06-11	Rg1 antibodies and uses thereof
SI1551805T1 (en)	2013-07-31	Substituted gamma-phenyl-delta-lactams and uses related thereto
AU2003296369A8 (en)	2004-06-30	Imminoamines and preparation thereof
IL172510A0 (en)	2006-04-10	Antibodies and uses thereof
IL166063A0 (en)	2006-01-15	Antibodies and uses thereof
AU2003219093A8 (en)	2003-10-08	Anti-hpv-16 e7 antibodies and their use
IL165112A0 (en)	2005-12-18	Variant integrinpolypeptides and thereof
AU2003231827A8 (en)	2003-12-12	Pseudo-tissues and uses thereof
AU2003249533A8 (en)	2004-01-23	Neoplasm specific antibodies and uses thereof
AU2003298739A8 (en)	2004-06-18	Intermedin and its uses
AU2003302173A8 (en)	2004-07-14	Spirotetrathiocarbamates and spirooxothiocarbamates
GB0226878D0 (en)	2002-12-24	Antibodies
AU2003228397A8 (en)	2003-10-20	Hausp-p53 interaction and uses thereof
AU2003216442A8 (en)	2003-09-09	Enkurin and uses thereof
GB0227080D0 (en)	2002-12-24	Antibodies and uses thereof
AU2003270518A8 (en)	2004-04-30	Therapeutic anti-bgp(c-cam1) antibodies and uses thereof

Legal Events

Date	Code	Title	Description
2013-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)